Los Angeles Capital Management LLC Has $426,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Los Angeles Capital Management LLC trimmed its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 6.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,380 shares of the company’s stock after selling 1,520 shares during the period. Los Angeles Capital Management LLC’s holdings in ORIC Pharmaceuticals were worth $426,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ORIC. BlackRock Inc. lifted its position in shares of ORIC Pharmaceuticals by 18.8% during the second quarter. BlackRock Inc. now owns 2,270,310 shares of the company’s stock worth $40,162,000 after purchasing an additional 359,957 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of ORIC Pharmaceuticals by 18.6% during the third quarter. Victory Capital Management Inc. now owns 1,546,323 shares of the company’s stock worth $32,334,000 after purchasing an additional 241,963 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its position in shares of ORIC Pharmaceuticals by 33.3% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 742,666 shares of the company’s stock worth $15,529,000 after purchasing an additional 185,456 shares in the last quarter. Morgan Stanley lifted its position in shares of ORIC Pharmaceuticals by 1,033.2% during the second quarter. Morgan Stanley now owns 146,015 shares of the company’s stock worth $2,582,000 after purchasing an additional 133,130 shares in the last quarter. Finally, Emerald Advisers LLC lifted its position in shares of ORIC Pharmaceuticals by 20.5% during the third quarter. Emerald Advisers LLC now owns 726,236 shares of the company’s stock worth $15,186,000 after purchasing an additional 123,478 shares in the last quarter. Institutional investors own 92.51% of the company’s stock.

Shares of NASDAQ ORIC opened at $12.80 on Friday. The company’s 50 day simple moving average is $15.15 and its 200 day simple moving average is $17.68. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $11.28 and a fifty-two week high of $39.45. The firm has a market capitalization of $504.09 million, a P/E ratio of -5.49 and a beta of 1.83.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, November 8th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.11. Equities research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.11 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on ORIC shares. HC Wainwright upped their target price on shares of ORIC Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 10th. Zacks Investment Research upgraded shares of ORIC Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 12th. Robert W. Baird cut their price objective on shares of ORIC Pharmaceuticals from $47.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, October 8th. Finally, Citigroup cut their price objective on shares of ORIC Pharmaceuticals from $33.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, October 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, ORIC Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $28.17.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.

See Also: How to read a candlestick chart

Want to see what other hedge funds are holding ORIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC).

Institutional Ownership by Quarter for ORIC Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.